NASDAQ · Key Statistics

IRulya Therapeutics Inc. (IRLA) P/E Ratio, ROE & Key Statistics

$38.45 NASDAQ: IRLA Market Cap $39.11M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for IRulya Therapeutics Inc. (IRLA), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-1.88
P/B ratioShare price divided by book value per share.-7.27
P/S ratioMarket value divided by annual revenue.0.00
PEG ratioP/E divided by the earnings growth rate.-0.01
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-0.01
EV / RevenueEnterprise value against annual revenue.0.00
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-53.19%
Free cash flow yieldFree cash flow as a percentage of market value.-115.89%
Price / free cash flowMarket value divided by free cash flow.-0.86

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.0.00%
Operating marginRevenue left after operating costs.0.00%
Net marginRevenue left after every cost, including tax and interest.0.00%
Return on equityProfit as a percentage of shareholders’ equity.233.33%
Return on assetsProfit as a percentage of total assets.-100.29%
Return on capital employedOperating profit against the capital the business uses.-126.06%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.14.72
Quick ratioThe same, excluding inventory.14.72
Cash ratioCash alone against current liabilities.0.14
Debt to equityTotal borrowings against shareholders’ equity.-0.50
Debt to assetsTotal borrowings against total assets.0.19
Interest coverageHow many times operating profit covers the interest bill.0.00

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$336.00
Book value per shareShareholders’ equity divided by shares outstanding.$6.51
Market capitalisationShare price times shares outstanding.$39.11M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$478988

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

IRulya Therapeutics Inc. (IRLA) statistics — frequently asked questions

What is IRulya Therapeutics Inc.'s P/E ratio?

IRulya Therapeutics Inc. (IRLA) trades on a price-to-earnings ratio of -1.88. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is IRulya Therapeutics Inc.'s return on equity?

IRulya Therapeutics Inc. (IRLA) reports a return on equity of 233.33%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does IRulya Therapeutics Inc. carry?

IRulya Therapeutics Inc. (IRLA) has a debt-to-equity ratio of -0.50, which compares total borrowings with shareholders' equity.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.